Kristin Marvin Keller

Kristin Keller is the Chief Commercial Officer of Q BioMed, focused on driving the global commercialization of its in-market product, Strontium89, as well as contributing strategic insight and direction to the company’s portfolio of earlier stage assets. Kristin is a seasoned pharmaceutical marketer and strategist with deep experience in the specialty and orphan drug space. She has spent over 20 years working on pharmaceutical, biotech and medical device brands for both small biotech companies such as Actelion, Raptor, Alexion and Biomarin as well as larger pharma like Novartis, Sanofi, AstraZeneca and Roche. She has helped lead the global commercial strategy development and execution of many notable launches, particularly in the rare disease space. Kristin received a bachelor’s degree in developmental psychology from Mills College after completing an honors pre-med/biochemistry program at the University of Massachusetts-Amherst.